Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
AAPS open
| AAPS open |
| Pubbl/distr/stampa | London, United Kingdom : , : Springer, , [2015]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Pharmaceutical technology
Drugs - Design Farmacologia Revistes electròniques Pharmaceutical Preparations Drug Design Techniques pharmaceutiques Médicaments - Conception Médicaments |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 2364-9534 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | American Association of Pharmaceutical Scientists open |
| Record Nr. | UNINA-9910137216903321 |
| London, United Kingdom : , : Springer, , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
AAPS open
| AAPS open |
| Pubbl/distr/stampa | London, United Kingdom : , : Springer, , [2015]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Pharmaceutical technology
Drugs - Design Farmacologia Revistes electròniques Pharmaceutical Preparations Drug Design Techniques pharmaceutiques Médicaments - Conception Médicaments |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 2364-9534 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | American Association of Pharmaceutical Scientists open |
| Record Nr. | UNISA-996217618803316 |
| London, United Kingdom : , : Springer, , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Absorption and drug development [[electronic resource] ] : solubility, permeability, and charge state / / Alex Avdeef
| Absorption and drug development [[electronic resource] ] : solubility, permeability, and charge state / / Alex Avdeef |
| Autore | Avdeef Alex |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (742 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Drugs - Design
Drugs - Metabolism Drug development Absorption |
| ISBN |
1-62198-226-2
1-280-58934-5 9786613619174 1-118-28603-0 1-118-28606-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Transport model -- pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability - Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier. |
| Record Nr. | UNINA-9910141449403321 |
Avdeef Alex
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ACS combinatorial science
| ACS combinatorial science |
| Pubbl/distr/stampa | Washington, DC, : American Chemical Society, [2011]-[2020] |
| Disciplina | 543 |
| Soggetto topico |
Combinatorial chemistry
QSAR (Biochemistry) Drugs - Design |
| Soggetto genere / forma | Periodicals. |
| ISSN | 2156-8944 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
American Chemical Society combinatorial science
Combinatorial science ACS comb. sci |
| Record Nr. | UNINA-9910138754803321 |
| Washington, DC, : American Chemical Society, [2011]-[2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME Processes in Pharmaceutical Sciences [[electronic resource] ] : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga
| ADME Processes in Pharmaceutical Sciences [[electronic resource] ] : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga |
| Autore | Talevi Alan |
| Edizione | [2nd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (489 pages) |
| Disciplina | 615.19 |
| Altri autori (Persone) | QuirogaPablo A |
| Soggetto topico |
Pharmaceutical chemistry
Pharmacology Toxicology Pharmacy Drugs - Design Pharmaceutics Structure-Based Drug Design |
| ISBN | 3-031-50419-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1: The basics of ADME processes -- Chapter 1-Introduction. Biopharmaceutics and Pharmacokinetics -- Chapter 2-Drug release -- Chapter 3-Drug Absorption -- Chapter 4-Drug Distribution -- Chapter 5-Drug Metabolism -- Chapter 6-Drug Excretion -- Chapter 7-Drug Delivery Routes -- Chapter 8-Compartmental Pharmacokinetic Models -- Chapter 9-Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models -- Chapter 10-Drug Drug and Food Drug Interactions of Pharmacokinetic Nature -- Part 2: Specialized topics -- Chapter 11-Nanocarriers: Delivery Routes -- Chapter 12-Advanced Techniques for Quality Assessment of Nanocarriers -- Chapter 13-Nanomedicines Obtained by Nanoprinting -- Chapter 14-Absorption, Distribution, Metabolism and Excretion of Biopharmaceutical Drug Products -- Chapter 15-In silico and in vitro ADME predictions -- Chapter 16-Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens -- Chapter 17-The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics -- Chapter 18-Bioavailability and Bioequivalence studies -- Chapter 19-Drug transporters – Physiological role and Their Impact on Pharmacotherapy -- Chapter 20-Blood Flow Distribution and Membrane Transporters As Determinant Factors Of Tissue Drug Concentration. |
| Record Nr. | UNINA-9910847085703321 |
|
Talevi Alan
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910141254203321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910816078003321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| Soggetto genere / forma | Electronic books. |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910140756503321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910830524603321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910840962203321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Drugs - Design
(307)
- Pharmaceutical chemistry (91)
- Drug development (68)
- Drug Design (35)
- Biopharmaceutics (16)